

**From:** Davena Norris davena.norris@gmail.com

**Subject:** Written Testimony for Dorothy Moller's presentation on 7/22/25

**Date:** July 23, 2025 at 6:49 AM

**To:** Eleanor Chavez eleanorchavez@gmail.com, eleanor.chavez@nmlegis.gov, Thomson, Liz liz.thomson@nmlegis.gov, dawson@nmlegis.gov

**Bcc:** feldblum2487@gmail.com

DN

Dear Representatives Thomson and Chavez,

I am submitting written testimony regarding Dorothy Moller's presentation to LHHSC yesterday. Although I was present to speak, I was unable to do so due to a technical issue with my microphone. I kindly ask that you share this with the committee.

I am a Pharmacist Clinician in Las Cruces, serving patients in both hospital and family medicine settings. Rising healthcare and drug costs are deeply concerning, and I appreciate LHHSC's efforts to explore meaningful solutions. I offer the following observations and recommendations:

1. **Dorothy Moller's Report:** I was very impressed with her report. It demonstrates the value of investing in expert consultants to analyze key cost drivers in healthcare. I hope she will also present her findings to the Legislative Finance Committee. Continued funding for this work is essential.
2. **Roadmap:** I support Mary Feldblum's proposal to form a committee of experts to develop a strategic roadmap. I recommend including a pharmacist—such as one from the New Mexico Pharmacists Association or the UNM College of Pharmacy—to provide valuable clinical and policy insight.
3. **Purchasing Strategy and Pricing Models:** I agree we should explore joining a purchasing consortium or establishing a state pharmaceutical purchasing board. Additionally, reference pricing and value-based contracts for specialty drugs warrant consideration.
4. **Polypharmacy and Medication Management:** I appreciate the discussion on polypharmacy and adverse drug events. As part of my role, I conduct comprehensive medication management (CMM), reviewing regimens to address drug therapy problems such as drug-drug and drug-disease state interactions. I frequently de-prescribe medications. Incorporating more clinical pharmacists into care teams can significantly improve medication safety and effectiveness.

Thank you for your continued work and consideration.

Sincerely,

Davena Norris, PharmD, PhC, BCPS, DipACLM